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SuMMARy – An increase in the incidence of breast cancer in women aged <40 years in conjun-
ction with a pronounced shift towards later childbearing has been reported in recent years. because 
survival from breast cancer in women of childbearing age has significantly improved, they are often 
concerned whether subsequent pregnancy will alter their risk of disease recurrence. in the modern 
era, the prognosis of pregnancy-associated breast cancer is comparable to non-pregnancy-associated 
breast cancer and women can bear children after breast cancer treatment without compromising 
their survival. Therefore, they should not be discouraged from becoming pregnant, and currently the 
usual waiting time of at least 2 years after the diagnosis of breast cancer is recommended. However, a 
small, nonsignificant adverse effect of pregnancy on breast carcinoma prognosis among women who 
conceive within 12 months of breast cancer diagnosis and a higher risk of relapse in women younger 
than 35 up to 5 years of the diagnosis may be found. Fortunately, for women with localized disease, 
earlier conception up to six months after completing their treatment seems unlikely to reduce their 
survival. ongoing and future prospective studies evaluating the risks associated with pregnancy in 
young breast cancer survivors are required. 
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Introduction
breast cancer incidence increases with age, with 
the vast majority of women diagnosed after the age of 
40. nevertheless, approximately 7% of women with 
breast cancer are diagnosed before age 40, and this 
disease accounts for more than 40% of all cancers in 
women in this age group1. in women in developed 
countries, breast cancer is the most common cancer 
and 12% of breast cancer occur in women aged 20-
342. However, an increase in the incidence of breast 
cancer in women aged <40 has been reported in re-
cent years in many western countries. The mean an-
nual changes in the incidence for the calendar period 
1995-2006 from all european cancer registries were 
1.032 (95%Ci=1.019-1.045) and 1.014 (95%Ci=1.010-
1.018) in women aged 20-29 and 30-39 at diagnosis, 
respectively3. in the uSA, the incidence of breast can-
cer with distant involvement at diagnosis increased in 
25- to 39-year-old women from 1.53 per 100,000 in 
1976 to 2.90 per 100,000 in 2009. This is an abso-
lute difference of 1.37 per 100,000, representing the 
mean compounded increase of 2.07% per year over 
the 34-year interval4. in Croatia in women aged 25-
30, the incidence is only 0.57/100,000, which means 
that about 4 cases of breast cancer during pregnancy 
and 4 cases of pregnacies after completed treatment of 
breast cancer can be expected per year5.
Many countries of the developed world have expe-
rienced a pronounced shift towards later childbearing 
in recent years. An increasing trend towards delay in 
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childbearing from 30 to 40 years of age for different 
reasons, in addition to improved diagnostic and thera-
peutic methods is concordant with the increasing in-
cidence of breast cancer in women that have not yet 
completed their family. it seems highly likely that in 
older women, the first full-term pregnancy increases 
the risk of breast cancer, whereas early age at full-term 
pregnancy appears to lower the risk. Although the 
definitive mechanism through which early pregnancy 
protects from breast cancer remains unclear, several 
hypotheses have been proposed, such as changes to 
the hormonal profile of parous women, differences in 
the estrogen responsiveness of the mammary gland, 
and the fact that a more differentiated mammary 
gland is less susceptible to carcinogens6. These age de-
pendent relationships may be partly explained by the 
high proportion of estrogen receptor-negative tumors 
in younger women (<35 years), whereas delayed child-
bearing represents a risk factor for estrogen receptor-
positive tumors among older premenopausal women7. 
An increased breast cancer risk with advancing mater-
nal age at first childbirth is supported by a relative risk 
of 3.7 (95%Ci: 1.30-10.5) in women with an estimat-
ed first median age of 41 years, compared with those 
with an estimated first birth age of 23 years8. in re-
cent decades, considerable reduction in breast cancer-
related death has been achieved with adjuvant thera-
pies (chemotherapy, endocrine and targeted therapies, 
radiotherapy) but at the cost of significant long-term 
consequences, including infertility. Reproductive is-
sues are of great importance to young women, in par-
ticular those that have not completed their families 
before breast cancer diagnosis9. There is the need to 
educate young patients regarding fertility issues at the 
moment of diagnosis10. Fortunately, pregnancy after 
breast cancer does not appear to confer poor progno-
sis. Moreover, a higher rate of pregnancy than expect-
ed was found after treatment, possibly due to newer 
treatments including fertility preservation and also 
possibly due to active fertility counseling programs11. 
in the past, women were counseled against pregnancy, 
based on the theory that elevated levels of estrogen and 
progesterone in pregnancy could increase the risk of 
breast cancer recurrence. However, current data show 
no increase in the risk of recurrence and no difference 
in survival in women who have children after breast 
cancer therapy as compared with women who choose 
not to become pregnant. As a result, breast cancer is 
no longer considered an absolute contraindication for 
subsequent pregnancies. A meta-analysis of 14 studies 
has confirmed that pregnancy in women with a his-
tory of breast cancer is safe and does not compromise 
their overall survival12. However, there is no informa-
tion to estimate the impact of later pregnancies on the 
risk of recurrence in women with pregnancy-associ-
ated breast cancer. in a recent case report, the first 
description of a pregnancy-associated recurrence in 
a patient previously treated for pregnancy-associated 
breast cancer has been described13. 
This paper reviews the literature regarding the in-
fluence of subsequent pregnancy on the prognosis in 
breast cancer survivors.
Survival of Patients with Pregnancy after Breast 
Cancer 
treatment of young women with breast cancer is 
usually the same as for older women. However, breast 
cancers in younger women are generally diagnosed at 
a later stage with more aggressive features and have 
inferior outcomes14. Therefore, young age represents 
an independent adverse prognostic factor for their 
survival in spite of more anthracycline-based adjuvant 
chemotherapy and hormonal therapy with tamoxifen 
in patients with positive lymph nodes and those with 
positive hormonal receptors15. However, recent ad-
vances in the field of adjuvant therapy in breast cancer 
have led to significant improvements in breast cancer 
survival. This has resulted in a progressive decline in 
breast cancer-related mortality, so that in 2010 there 
were estimated to be 400,000 breast cancer survivors 
under age 40 in the uSA. Hence, enquiry into the 
feasibility of fertility preservation, subsequent preg-
nancy and breastfeeding is increasingly encountered16. 
Therefore, women of childbearing age with breast 
cancer are often concerned about whether they will 
become infertile after treatment, and in those who 
wish to bear children, whether a subsequent pregnan-
cy will alter their risk of disease recurrence17. Concerns 
about premature menopause and infertility are com-
mon in younger women and have a role in the level of 
distress after treatment18. if a woman desires to bear 
children after her breast cancer treatment, she should 
be advised on fertility preservation options. Fertil-
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ity preservation issues should be discussed within a 
multidisciplinary environment, including oncologists 
and fertility specialists, and these fertility procedures 
must be initiated as early as possible prior to starting 
systemic therapy. young women should benefit from 
currently applied options, such as cryopreservation of 
embryos, oocytes, ovarian tissue and ejaculated or sur-
gically retrieved sperms prior to treatment. However, 
this procedure requires in vitro fertilization and thus 
a participating male partner (or sperm donor). oo-
cyte and ovarian tissue cryopreservation are emerging 
options for women who do not have a male partner 
at diagnosis. However, most of these procedures are 
considered experimental, and there are limited data 
regarding the safety of such strategies. For this reason, 
they can only be contemplated after adequate counsel-
ing and should be limited to storage of gonadal tis-
sue or whole gonads14,19. Among multiple strategies, 
controlled ovarian stimulation for embryo or oocyte 
cryopreservation is currently the best established 
method for fertility preservation. Current treatment 
protocols offer a minimal time delay until oncologic 
treatment is commenced. in urgent settings, random-
start ovarian stimulation represents a new technique 
that provides significant advantage by decreasing 
the total time of the treatment, and because it may 
be started irrespective of the phase of the cycle with-
out compromising oocyte yield and maturity before 
cancer treatment. However, in patients with estrogen-
sensitive cancers, stimulation protocols using letrozole 
are currently preferred over tamoxifen regimens, and 
therefore it may be highly advisable to use letrozole 
with gonadotropins routinely as a safe, effective and 
novel protocol of ovulation induction20. breast cancer 
survivors may be at risk of recurrent disease during 
subsequent pregnancy because they may be suscep-
tible to the hormonal changes of pregnancy, stimu-
lating growth of any remaining breast cancer cells or 
dormant micrometastases with subsequent pregnan-
cies17. The influence of subsequent pregnancy on the 
prognosis of the disease is usually regarded through its 
effect on patient survival, observing survival rates or 
relative risks, and appearence of recurrence or distant 
metastases21. 
in non-population based studies employing case-
matching methodology, which have provided more 
data to allow analysis of 5- and 10-year survival rates, 
there appears to be a survival advantage in the group 
of cases in comparison with controls. This survival 
superiority presented in survival rates is also ob-
served in those patients with negative lymph nodes, 
and compares favorably with patients with positive 
lymph nodes in both case control studies and case 
series. The literature in any earlier or later published 
series indicates that subsequent pregnancy in women 
with breast cancer does not decrease their survival. 
Moreover, survival rates in breast cancer patients who 
have subsequently become pregnant are good, often 
the same and sometimes even better than in patients 
without subsequent pregnancy12,16. in an earlier study 
by Mignot et al.22, it was demonstrated that there was 
no significant difference in survival curves because the 
10-year survival rate in patients who conceived after 
breast cancer treatment was 71% (90% in those with 
nodes - cancer and 71% in those with nodes + cancer, 
with no significant difference between the cases and 
controls in each group). Clark and Chua23 report that 
subsequent pregnancies taking place at least one year 
and preferably two years after treatment for breast 
cancer do not affect patient survival. Moreover, sub-
sequent pregnancy may confer an improved prognosis. 
Lethaby et al.24 also found no significant differences 
in survival between the women who had pregnancies 
subsequent to diagnosis of breast cancer and breast 
cancer patients who did not conceive. gelber et al.25 re-
port that subsequent pregnancy does not adversely af-
fect the prognosis of early-stage breast cancer because 
overall 5- and 10-year survival percentages measured 
among patients who became pregnant were 92% and 
86%, respectively, and survival in the matched com-
parison group was 85% at 5 years and 74% at 10 years 
The superior survival rate may merely reflect a healthy 
patient selection bias, but it is also consistent with an 
antitumor effect of pregnancy. in a study by Largil-
lier et al.26, it was found that pregnancy subsequent 
to breast cancer therapy resulted in a 77% decrease of 
death in women younger than 35. 
The population-based studies tried to avoid the 
recollection bias prevalent in the retrospective stud-
ies, but perhaps they added bias in the choice of con-
trol subjects for matching. These studies in addition 
to retrospective studies have shown that subsequent 
pregnancy results in an improvement of survival with 
favorable relative risks between 0.2 (0.1-0.5) and 0.8 
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(0.3-2.3). in a study by Sankila et al.27, it was found 
that controls had a 4.8-fold risk of death compared 
with those who delivered after a diagnosis of breast 
cancer. Their interpretation of this result was a “healthy 
mother effect” (i.e. that only women who feel healthy 
give birth and those who are affected by the disease do 
not). von Schoultz et al.28 found that the relative haz-
ard for women who became pregnant after diagnosis of 
breast cancer in comparison with women without sub-
sequent pregnancy was 0.48, which suggested a possi-
ble decreased risk of distant dissemination. Kroman et 
al.29 report that women who had full-term pregnancy 
after breast-cancer treatment had a non-significantly 
reduced risk of death (relative risk 0.55) compared with 
women who had no full-term pregnancy. in a study 
by velentgas et al.30, the age-adjusted relative risk of 
death associated with any subsequent pregnancy was 
0.8. Although the findings of the study were based 
on a small number of deaths, they do not suggest that 
pregnancy after a diagnosis of breast carcinoma has 
an adverse effect on survival. Mueller et al.31 found 
that women with child births occurring 10 months or 
more after diagnosis had a significantly decreased risk 
of dying (relative risk = 0.54), compared with women 
without subsequent child births. it has been suggested 
that the results of the study may provide some reassur-
ance to young women with breast carcinoma that sub-
sequent childbearing is unlikely to increase their risk 
of mortality. blakely et al.32 report that the incidence 
of disease recurrence was 23% in women who experi-
enced pregnancy and 54% in women who did not. The 
hazard ratio for disease recurrence in patients with 
post-treatment pregnancy was 0. in a repeated study 
by Kroman et al.33, it was found that women who had 
full-term pregnancy subsequent to breast cancer treat-
ment had a reduced risk of dying (relative risk 0.73), 
compared with other women with breast cancer. in 
line with their previous study, but based on more than 
twice the patient material, they found no evidence 
that pregnancy after treatment of breast cancer had 
negative influence on the prognosis. Kranick et al.34 
report that in women with and without subsequent 
pregnancy, neither the risk of recurrence nor death 
differed significantly by subsequent pregnancy history 
during an average 12-year follow up (adjusted hazard 
ratio recurrence 1.2; adjusted hazard ratio death 1.0). 
in a recent study, Litton35 found that for breast can-
cer survivors, there does not appear to be an increased 
risk of death associated with subsequent pregnancies 
when compared with breast cancer patients who did 
not have subsequent pregnancies. A meta-analysis by 
Azim et al.12 suggested the pregnancy after a diagnosis 
of breast cancer to be associated with improved sur-
vival when compared to breast cancer patients that did 
not have pregnancy after their diagnosis. The women 
who became pregnant following breast cancer diag-
nosis had a 41% reduced risk of death compared to 
women who did not become pregnant. Hence, breast 
cancer survivors should not be denied the opportunity 
of future conception. 
excluding the effects of pregnancy after breast 
cancer on survival rates and relative risks, other out-
come measures include recurrence and incidence of 
distant metastases. Sutton et al.36 found a recurrence 
rate of 28% in the pregnancy group and 46% in the 
non-pregnant group. With regard to distant metas-
tasis, von Schoulz et al.28 report a rate of 8% among 
all patients who became pregnant, compared with a 
rate of 24% among patients without subsequent preg-
nancy. Similarly, Malamos et al.37 report a 14% rate 
of local recurrence in the pregnant group and 39% in 
the non-pregnant group. Kajouharova et al.38 found an 
incidence of distant metastases of 15% among all pa-
tients who became pregnant subsequent to surgery for 
breast carcinoma. Therefore, it is evident that preg-
nancy may not have an adverse effect on the incidence 
of recurrence or poor survival in patients previously 
treated for breast cancer.
Interval from Diagnosis of Breast Cancer to 
Pregnancy
The optimal time to delay pregnancy following 
diagnosis and treatment of breast cancer is unknown 
and it is an important issue for all patients consider-
ing pregnancy. The definition of this time interval is 
variable because some studies use the period from 
the time of diagnosis to the time of delivery, which 
excludes abortions, whilst others use the time from 
diagnosis of breast cancer to diagnosis of pregnancy, 
which will then include all abortions21. The risk of re-
lapse and the time to recurrence is related to many 
factors including the stage, grade and nodal status, 
as well as the hormone receptor status39. From ear-
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lier to current studies, the usual practice recommends 
waiting for at least 2 years between diagnosis of early 
breast cancer and pregnancy, as most recurrences will 
develop in this time26. previous reports suggest that 
women who survive breast cancer and subsequently 
conceive have at least equivalent, if not better, surviv-
al than similar women matched for age and stage of 
cancer who do not subsequently conceive25,39. Saphner 
et al.40 have reported that the risk of recurrence was 
greatest (13.3%) in the interval between year 1 and 
2 after surgery. This risk then decreased consistently, 
and beyond 5 years averaged at about 4.3% per year in 
women with hormone receptor positive breast cancer. 
However, patients with hormone receptor negative 
tumors had a higher hazard of recurrence in years 0-5, 
which then decreased over time, whereas the hazard 
of recurrence for women with hormone receptor posi-
tive cancers was relatively constant in the first 5 years 
after diagnosis and from years 5 to 12. gelber et al.25 
report a better survival rate in those women who had 
subsequent pregnancy (overall 5-year survival rate of 
92% versus 85% in cases versus controls), even though 
43% of cases completed pregnancy within 1 year of di-
agnosis. Although in a recent study by Litton35, there 
does not appear to be an increased risk of death asso-
ciated with subsequent pregnancies for breast cancer 
survivors when compared with controls, waiting for 
at least 2 years is recommended because it may con-
vey a protective effect. Kranick et al.34 in their study 
found that neither the risk of recurrence nor death 
differed significantly by subsequent pregnancy his-
tory during an average 12-year follow up. Although 
the number of cases was limited, subgroup analyses 
indicated a small, nonsignificant adverse effect among 
women who conceived within 12 months of diagnosis. 
on the other hand, Largillier et al.26 found a high risk 
of relapse in women aged under 35. Therefore, it may 
be preferable to postpone pregnancy in these patients 
beyond 5 years after breast cancer therapy. However, 
ives et al.41 do not support the current medical advice 
given to all premenopausal women with a diagnosis 
of breast cancer to wait for 2 years before attempt-
ing to conceive. This recommendation may be valid 
only for women who are receiving treatment or have 
systemic disease at diagnosis. on the other hand, for 
women with localized disease, conception as early as 
six months after completing their treatment is un-
likely to reduce survival. The results reflect the clini-
cal recommendation that women delay pregnancy for 
two years after diagnosis and suggest that women who 
have good prognosis need not wait for two years to 
become pregnant. 
it is advisable that pregnancy be avoided during 
active treatment of breast cancer and several years 
after, so appropriate, acceptable and effective contra-
ception is a priority. Those who have completed their 
childbearing should be advised about permanent ster-
ilization. However, in cases when childbearing has 
not been completed, the use of natural family plan-
ning and barrier contraceptives is recommended to 
prevent undesired pregnancy while the risk of relapse 
is present42.
Hypothesis on Survival
The good survival rate consistently observed in 
reviews, often the same or better for patients who 
become pregnant subsequent to a diagnosis of breast 
cancer than in patients with no subsequent pregnancy, 
may in part be due to the bias of retrospective studies. 
one possible explanation for this supposed survival 
advantage is the ‘healthy mother effect,’ as women 
who feel healthy may be more likely to conceive, lead-
ing to selection bias27. However, there are also biologi-
cal theories as to why pregnancy may protect against 
relapse, such as alloimmunization against breast can-
cer cells. it is postulated that breast carcinoma cells 
and fetal cells share common antigens, representing 
a basis for isoimmunization that occurs during preg-
nancy. The fetal antigen hypothesis has confirmed the 
presence of a tumor-specific antigen, MuC1, on both 
fetal and breast cancer tissues. Multiparous women 
also generate anti-MuC1 major histocompatibility 
complex-restricted cytotoxic t cell cytolytic activity 
against MuC1-bearing tumor cell lines43. because 
the mammary gland is exposed to the highest physi-
ological concentrations of estradiol and progesterone 
during full-term pregnancy, it is possible that these 
elevated levels of hormones induce cytotoxic effects 
and protection from mammary cancer44. if a woman 
has full-term pregnancy and has not already had a 
prior initiation event, then the pregnancy would be 
expected to leave the breast tissue more differentiated 
and less susceptible to carcinogenic influences at long 
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term45. in women with bRCA1 or 2 gene mutations, 
the risks of pregnancy are not well established. obser-
vational studies suggest that bRCA1 mutation carriers 
who have their first child at 30 years or older may have 
a reduced personal risk of breast cancer. However, the 
opposite effect has been observed in bRCA2 mutation 
carriers where late first pregnancies (over 30 years) are 
linked with an increased risk of breast cancer46. in a 
recent multi-center cohort study in 12,084 women 
with a bRCA1 or bRCA2 mutation, there were 128 
case subjects who were diagnosed with breast cancer 
while pregnant or who became pregnant after the di-
agnosis of breast cancer. it was found that pregnancy 
concurrent with or after a diagnosis of breast cancer 
does not appear to adversely affect survival among 
bRCA1/2 mutation carriers47. Therefore, young breast 
cancer patients who have not completed their family 
should not be discouraged from becoming pregnant 
when they wish to, since there is no adverse effect 
of pregnancy on survival. Although fertility may be 
impaired by chemotherapy, births seem to sustain no 
adverse effects, while breastfeeding appears to be fea-
sible and safe48. in addition, it has recently been found 
that microchimerism may be highly relevant to later 
cancer development. detection of male microchime-
rism was strongly associated with a reduced risk of 
developing breast cancer and also an increased risk of 
developing colon cancer. Lower concentrations of y 
chromosome from previous pregnancies with a male 
fetus have been found in women with breast cancer 
(40%) as compared with cancer-free women (70%). 
Therefore, lower concentrations of microchimerism 
may predate cancer diagnosis, and higher levels may 
indicate a possible beneficial effect on breast cancer 
development49.
Conclusions 
There is a wide perception that subsequent preg-
nancy may worsen the prognosis of young breast can-
cer survivors. in many earlier and current studies, it 
has been found that pregnancy is not associated with 
an increased risk of disease recurrence or poorer sur-
vival in patients previously treated for breast carcino-
ma. Therefore, young breast cancer patients who have 
not completed their family should not be discour-
aged from becoming pregnant, and the current usual 
waiting time of at least 2 years after the diagnosis of 
breast cancer is recommended. However, a small, ad-
verse effect of pregnancy on breast carcinoma prog-
nosis among women who conceive within 12 months 
of breast cancer diagnosis and a higher risk of relapse 
in women aged less than 35 for up to 5 years may be 
found. Fortunately, for women with localized disease, 
earlier conception up to six months after completing 
their treatment seems unlikely to reduce their surviv-
al. ongoing and future prospective studies evaluating 
the risks associated with pregnancy for young breast 
cancer survivors are required.
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Sažetak
KASniJA tRudnoćA i pRognoZA Kod pReživJeLiH od RAKA doJKe
M. Kasum, L. Beketić-Orešković i S. Orešković
u posljednje vrijeme izvješćuje se o sve većoj pojavnosti raka dojke skupa s izraženijim odgađanjem rađanja kod žena 
mlađih od 40 godina. budući da se preživljenje žena generativne dobi zbog raka dojke značajno poboljšalo, one su često 
zabrinute hoće li kasnija trudnoća doprinijeti opasnosti od recidiva bolesti. u današnje vrijeme prognoza raka dojke u 
trudnoći je usporediva s rakom dojke koji nije u svezi s trudnoćom i žene mogu rađati djecu nakon liječenja raka dojke bez 
ugrožavanja njihovog preživljavanja. Stoga žene ne treba obeshrabriti u želji za trudnoćom, a uobičajene su preporuke da se 
pričeka s trudnoćom najmanje 2 godine nakon postavljene dijagnoze. ipak, malen i neznakovit nepovoljan učinak trudnoće 
na rak dojke može se naći među ženama koje zanesu unutar 12 mjeseci od dijagnoze raka dojke, a veća opasnost od recidiva 
kod žena mlađih od 35 godina do čak 5 godina nakon dijagnoze. Srećom, kod žena s lokaliziranom bolešću izgleda manje 
vjerojatno da bi ranija trudnoća do čak 5 mjeseci nakon završenog liječenja ugrozila njihovo preživljavanje. potrebna su 
daljnja istraživanja koja će procijenti rizike u svezi s trudnoćom kod mlađih osoba preživjelih od raka dojke. 
Ključne riječi: Rak dojke – komplikacije; Ženska osoba; Preživjele osobe; Trudnoća; Trudnoća, komplikacije tumora
